EZH2 and epithelioid sarcoma: Most epidrugs that has been approved by FDA are for the treatment of hematopoietic malignancies.284 Tazemetostat, a EZH2 inhibitor, was approved by FDA for advanced epithelioid sarcoma, making it the first epidrug to treat solid tumors.285 In this chapter, we will discuss some potential epigenetic therapeutic targets in LSCC.